论文部分内容阅读
蛋白激酶在肿瘤发生、发展过程中起重要作用,以其为药物靶点的激酶抑制剂成为近年药物研发与应用的热点。酪氨酸激酶抑制剂具有高选择性、不良反应少的特点,在慢性粒细胞白血病、胃肠间质瘤、非小细胞肺癌、肝细胞癌、肾细胞癌等多种疾病治疗中显示出较传统治疗药物的优越性,部分已成为治疗肿瘤的一线用药。
Protein kinases play an important role in tumorigenesis and development, and kinase inhibitors, which are used as drug targets, have become hot spots for drug development and application in recent years. Tyrosine kinase inhibitors with high selectivity, fewer adverse reactions, in chronic myeloid leukemia, gastrointestinal stromal tumors, non-small cell lung cancer, hepatocellular carcinoma, renal cell carcinoma and other diseases showed more treatment The superiority of traditional therapeutic drugs, some have become first-line treatment of cancer drugs.